BACKGROUND: Glucagon-like peptide 1 (GLP-1) is an incretin hormone, which stimulates glucose-dependent insulin secretion from the pancreas and holds immune-regulatory properties. A marked increase of GLP-1 has been found in critically ill patients. This study was performed to elucidate the underlying mechanism and evaluate its prognostic value. METHODS: GLP-1 plasma levels were determined in 3 different patient cohorts: 1) critically ill patients admitted to our intensive care unit (n = 215); 2) patients with chronic kidney disease on hemodialysis (n = 173); and 3) a control group (no kidney disease, no acute inflammation, n = 105). In vitro experiments were performed to evaluate GLP-1 secretion in response to human serum samples from the above-described cohorts. RESULTS: Critically ill patients presented with 6.35-fold higher GLP-1 plasma level in comparison with the control group. There was a significant correlation of GLP-1 levels with markers for the severity of inflammation, but also kidney function. Patients with end-stage renal disease displayed 4.46-fold higher GLP-1 concentrations in comparison with the control group. In vitro experiments revealed a strong GLP-1-inducing potential of serum from critically ill patients, while serum from hemodialysis patients only modestly increased GLP-1 secretion. GLP-1 levels independently predicted mortality in critically ill patients and patients with end-stage renal disease. CONCLUSIONS: Chronic and acute inflammatory processes like sepsis or chronic kidney disease increase circulating GLP-1 levels. This most likely reflects a sum effect of increased GLP-1 secretion and decreased GLP-1 clearance. GLP-1 plasma levels independently predict the outcome of critically ill and end-stage renal disease patients.
BACKGROUND:Glucagon-like peptide 1 (GLP-1) is an incretin hormone, which stimulates glucose-dependent insulin secretion from the pancreas and holds immune-regulatory properties. A marked increase of GLP-1 has been found in critically illpatients. This study was performed to elucidate the underlying mechanism and evaluate its prognostic value. METHODS:GLP-1 plasma levels were determined in 3 different patient cohorts: 1) critically illpatients admitted to our intensive care unit (n = 215); 2) patients with chronic kidney disease on hemodialysis (n = 173); and 3) a control group (no kidney disease, no acute inflammation, n = 105). In vitro experiments were performed to evaluate GLP-1 secretion in response to human serum samples from the above-described cohorts. RESULTS:Critically illpatients presented with 6.35-fold higher GLP-1 plasma level in comparison with the control group. There was a significant correlation of GLP-1 levels with markers for the severity of inflammation, but also kidney function. Patients with end-stage renal disease displayed 4.46-fold higher GLP-1 concentrations in comparison with the control group. In vitro experiments revealed a strong GLP-1-inducing potential of serum from critically illpatients, while serum from hemodialysis patients only modestly increased GLP-1 secretion. GLP-1 levels independently predicted mortality in critically illpatients and patients with end-stage renal disease. CONCLUSIONS: Chronic and acute inflammatory processes like sepsis or chronic kidney disease increase circulating GLP-1 levels. This most likely reflects a sum effect of increased GLP-1 secretion and decreased GLP-1 clearance. GLP-1 plasma levels independently predict the outcome of critically ill and end-stage renal diseasepatients.
Authors: Scott C Brakenridge; Frederick A Moore; Nicole R Mercier; Michael Cox; Quron Wu; Lyle L Moldawer; Alicia M Mohr; Philip A Efron; R Stephen Smith Journal: J Am Coll Surg Date: 2019-04-13 Impact factor: 6.113
Authors: Ahmed Al-Dwairi; Tamara E Alqudah; Othman Al-Shboul; Mohammad Alqudah; Ayman G Mustafa; Mahmoud A Alfaqih Journal: J Inflamm Res Date: 2018-03-20
Authors: Robert T Mankowski; Stephen D Anton; Gabriela L Ghita; Babette Brumback; Dijoia B Darden; Azra Bihorac; Christiaan Leeuwenburgh; Lyle L Moldawer; Philip A Efron; Scott C Brakenridge; Frederick A Moore Journal: J Gerontol A Biol Sci Med Sci Date: 2022-01-07 Impact factor: 6.591
Authors: Kürşat Gündoğan; Ender Doğan; Nurhayat Tuğra Özer; Gülşah Güneş Şahin; Serap Şahin; Murat Sungur; Ismail Hakki Akbudak; Sabahattin Muhtaroğlu; Muhammet Güven; Thomas R Ziegler Journal: Turk J Med Sci Date: 2020-04-27 Impact factor: 0.973